35523-64-9

Usage

Uses

Used in Pharmaceutical Industry:
2,3-diamino-6-methylpyrimidin-4(3H)-one is used as a key intermediate for the development of antiviral and antimicrobial drugs. Its unique structure allows for the creation of new drug candidates that can target specific pathogens effectively.
Used in Synthesis of Nucleoside Analogs:
2,3-diamino-6-methylpyrimidin-4(3H)-one is used as a building block in the synthesis of nucleoside analogs, which are important in the development of antiviral medications. These analogs can mimic the structure of natural nucleosides, thereby inhibiting viral replication.
Used in Heterocyclic Compounds Synthesis:
2,3-diamino-6-methylpyrimidin-4(3H)-one is used as a component in the synthesis of heterocyclic compounds, which are valuable in various chemical and pharmaceutical applications. Its presence in these compounds can lead to novel properties and potential uses.
Used in Development of Novel Materials:
2,3-diamino-6-methylpyrimidin-4(3H)-one is used as a precursor in the development of new materials, such as polymers and coatings, that can have unique properties due to the incorporation of 2,3-diamino-6-methylpyrimidin-4(3H)-one.
Used in Chemical Research:
2,3-diamino-6-methylpyrimidin-4(3H)-one is used as a research tool in chemical studies, allowing scientists to explore its reactivity, properties, and potential applications in various chemical processes.

Upstream product

• 141-97-9 ethyl acetoacetate 
• 1937-19-5 1-aminoguanidine hydrochloride 
• 79-17-4 aminoguanidine 

Downstream Products

• 1281860-66-9 2-(1,1-difluoroethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 28565-42-6 7-chloro-2-ethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine 
• 1282041-90-0 2-ethyl-5-methyl-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281860-97-6 5-methyl-2-(1-methylethyl)-N-[4-(trifluoromethyl)phenyl][1,2,4]-triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-92-2 5-methyl-2-(1-methylethyl)-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-00-4 2-cyclopropyl-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-93-3 2-cyclopropyl-5-methyl-N-[4-(pentafluoro-λ6-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-94-4 2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-06-0 2-(1,1-difluoroethyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-07-1 2-(1,1-difluoroethyl)-N-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1281861-08-2 N-(3,5-difluoro-4-(trifluoromethyl)phenyl)-2-(1,1-difluoroethyl)-5-methyl[1,2,4]triazolo-[1,5-a]pyrimidin-7-amine 
• 1281861-09-3 2-(1,1-difluoropropyl)-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1282041-95-5 2-(1,1-difluoropropyl)-5-methyl-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 
• 1315606-94-0 5-methyl-2-[2-(methyloxy)ethyl]-N-[4-(pentafluoro-λ6-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine 

Relevant academic research and scientific papers

FERROCHELATASE INHIBITORS AND METHODS OF USE

The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase in

NEW SUBSTITUTED TRIAZOLOPYRIMIDINES AS ANTI-MALARIAL AGENTS

The present invention is related to a use of triazolopyrimidine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to triazolopyrimidine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential

Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance. In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. The X-ray structure of PfDHODH was used to inform the medicinal chemistry program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite. This compound has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance. These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compound toward clinical candidate status.

ANTIMALARIAL AGENTS THAT ARE INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE

Inhibitors of parasitic dihydroorotate dehydrogenase enzyme (DHOD) are candidate therapeutics for treating malaria. Illustrative of such therapeutic agents include the compound: and a triazolopyrimidine class of compounds that conform to Formula (IX): and their solvates, stereoisomers, tautomers and pharmaceutically acceptable salts.

Formation, structure and heterocyclization of aminoguanidine and ethyl acetoacetate condensation products

Condensation of aminoguanidine hydrochloride and ethyl acetoacetate results in 2,3-diamino-6-methylpyrimidin-4(3H)-one, 5-hydroxy-1-carboxamidino-3- methylpyrazole or ethyl N-[(5-hydroxy-3-methylpyrazol-1-yl)imidoyl] aminocrotonoate depending on the type of the base. Formation of pyrazole derivatives occurs in the case of dequaternized substrate imine-group protonating by the acids formed as a result of ion exchange reaction. Chelate fragment of amidinohydroxypyrazole structure provides stabilization of this compound and stipulates its inertness towared the heterocycle closure.